ID   CPT2_HUMAN              Reviewed;         658 AA.
AC   P23786; B2R6S0; Q5SW68; Q9BQ26;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 2.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Carnitine O-palmitoyltransferase 2, mitochondrial;
DE            EC=2.3.1.21;
DE   AltName: Full=Carnitine palmitoyltransferase II;
DE            Short=CPT II;
DE   Flags: Precursor;
GN   Name=CPT2; Synonyms=CPT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=1988962; DOI=10.1073/pnas.88.2.661;
RA   Finocchiaro G., Taroni F., Rocchi M., Martin A.L., Colombo I.,
RA   Tarelli G.T., Didonato S.;
RT   "cDNA cloning, sequence analysis, and chromosomal localization of the
RT   gene for human carnitine palmitoyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:661-665(1991).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION TO 283 AND 375.
RX   PubMed=1961767; DOI=10.1073/pnas.88.23.10981;
RA   Finocchiaro G., Taroni F., Rocchi M., Martin A.L., Colombo I.,
RA   Tarelli G.T., Didonato S.;
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10981-10981(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CPT2D DEFICIENCY
RP   HIS-50 AND ASN-553.
RX   PubMed=7711730; DOI=10.1093/hmg/4.1.19;
RA   Verderio E., Cavadini P., Montermini L., Wang H., Lamantea E.,
RA   Finocchiaro G., Didonato S., Gellera C., Taroni F.;
RT   "Carnitine palmitoyltransferase II deficiency: structure of the gene
RT   and characterization of two novel disease-causing mutations.";
RL   Hum. Mol. Genet. 4:19-29(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], VARIANT CPT2D LEU-113, AND
RP   VARIANTS ILE-368 AND VAL-647.
RC   TISSUE=Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=2174799; DOI=10.1016/0014-5793(90)81354-Q;
RA   Finocchiaro G., Colombo I., Didonato S.;
RT   "Purification, characterization and partial amino acid sequences of
RT   carnitine palmitoyl-transferase from human liver.";
RL   FEBS Lett. 274:163-166(1990).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [13]
RP   VARIANT CPT2D LEU-227.
RA   Taroni F., Gellera C., Cavadini P., Baratta S., Lamantea E.,
RA   Dethlefs S., Didonato S., Reik R.A., Benke P.J.;
RT   "Lethal carnitine palmitoyltransferase (CPT) II deficiency in
RT   newborns: a molecular-genetic study.";
RL   Am. J. Hum. Genet. 51:A245-A245(1992).
RN   [14]
RP   INVOLVEMENT IN CPT2DI, VARIANT CPT2DI CYS-631, AND VARIANTS ILE-368
RP   AND VAL-647.
RX   PubMed=1528846; DOI=10.1073/pnas.89.18.8429;
RA   Taroni F., Verderio E., Fiorucci S., Cavadini P., Finocchiaro G.,
RA   Uziel G., Lamantea E., Gellera C., Didonato S.;
RT   "Molecular characterization of inherited carnitine
RT   palmitoyltransferase II deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:8429-8433(1992).
RN   [15]
RP   VARIANT CPT2D LEU-113.
RX   PubMed=8358442; DOI=10.1038/ng0793-314;
RA   Taroni F., Verderio E., Dworzak F., Willems P.J., Cavadini P.,
RA   Didonato S.;
RT   "Identification of a common mutation in the carnitine
RT   palmitoyltransferase II gene in familial recurrent myoglobinuria
RT   patients.";
RL   Nat. Genet. 4:314-320(1993).
RN   [16]
RP   INVOLVEMENT IN CPT2DI, AND VARIANT CPT2DI SER-628.
RX   PubMed=8651281;
RA   Bonnefont J.-P., Taroni F., Cavadini P., Cepanec C., Brivet M.,
RA   Saudubray J.-M., Leroux J.-P., Demaugre F.;
RT   "Molecular analysis of carnitine palmitoyltransferase II deficiency
RT   with hepatocardiomuscular expression.";
RL   Am. J. Hum. Genet. 58:971-978(1996).
RN   [17]
RP   VARIANTS CPT2D THR-214; LEU-448 AND PHE-479.
RA   Wieser T., Deschauer M., Zierz S.;
RT   "Carnitine palmityltransferase II deficiency: three novel mutations.";
RL   Ann. Neurol. 42:414-415(1997).
RN   [18]
RP   VARIANTS CPT2D LYS-174 AND TYR-383, AND VARIANTS CYS-352; ILE-368 AND
RP   VAL-647.
RX   PubMed=9600456;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<377::AID-HUMU5>3.0.CO;2-E;
RA   Wataya K., Akanuma J., Cavadini P., Aoki Y., Kure S., Invernizzi F.,
RA   Yoshida I., Kira J., Taroni F., Matsubara Y., Narisawa K.;
RT   "Two CPT2 mutations in three Japanese patients with carnitine
RT   palmitoyltransferase II deficiency: functional analysis and
RT   association with polymorphic haplotypes and two clinical phenotypes.";
RL   Hum. Mutat. 11:377-386(1998).
RN   [19]
RP   VARIANTS CPT2D LEU-113; GLN-151; LEU-227; ARG-550 AND SER-604, AND
RP   VARIANTS ILE-368 AND VAL-647.
RX   PubMed=9758712; DOI=10.1006/mgme.1998.2711;
RA   Yang B.-Z., Ding J.-H., Dewese T., Roe D., He G., Wilkinson J.,
RA   Day D.W., Demaugre F., Rabier D., Brivet M., Roe C.;
RT   "Identification of four novel mutations in patients with carnitine
RT   palmitoyltransferase II (CPT II) deficiency.";
RL   Mol. Genet. Metab. 64:229-236(1998).
RN   [20]
RP   VARIANTS CPT2D CYS-503 AND ASP-549.
RX   PubMed=10090476;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:3<210::AID-HUMU5>3.3.CO;2-S;
RA   Taggart R.T., Smail D., Apolito C., Vladutiu G.D.;
RT   "Novel mutations associated with carnitine palmitoyltransferase II
RT   deficiency.";
RL   Hum. Mutat. 13:210-220(1999).
RN   [21]
RP   INVOLVEMENT IN CPT2DLN.
RX   PubMed=11477613; DOI=10.1002/ajmg.1457;
RA   Elpeleg O.N., Hammerman C., Saada A., Shaag A., Golzand E.,
RA   Hochner-Celnikier D., Berger I., Nadjari M.;
RT   "Antenatal presentation of carnitine palmitoyltransferase II
RT   deficiency.";
RL   Am. J. Med. Genet. 102:183-187(2001).
RN   [22]
RP   VARIANTS CPT2D GLN-151; ASP-210; GLN-296 AND ARG-600, AND VARIANTS
RP   ILE-368 AND VAL-647.
RX   PubMed=14605500; DOI=10.1023/A:1025947930752;
RA   Olpin S.E., Afifi A., Clark S., Manning N.J., Bonham J.R., Dalton A.,
RA   Leonard J.V., Land J.M., Andresen B.S., Morris A.A., Muntoni F.,
RA   Turnbull D., Pourfarzam M., Rahman S., Pollitt R.J.;
RT   "Mutation and biochemical analysis in carnitine palmitoyltransferase
RT   type II (CPT II) deficiency.";
RL   J. Inherit. Metab. Dis. 26:543-557(2003).
RN   [23]
RP   VARIANT CPT2D GLN-296.
RX   PubMed=14615409; DOI=10.1097/01.LAB.0000098428.51765.83;
RA   Sigauke E., Rakheja D., Kitson K., Bennett M.J.;
RT   "Carnitine palmitoyltransferase II deficiency: a clinical,
RT   biochemical, and molecular review.";
RL   Lab. Invest. 83:1543-1554(2003).
RN   [24]
RP   VARIANTS CPT2D HIS-50; LEU-113 AND GLY-213.
RX   PubMed=15622536; DOI=10.1002/ana.20320;
RA   Oerngreen M.C., Dunoe M., Ejstrup R., Christensen E., Schwartz M.,
RA   Sacchetti M., Vissing J.;
RT   "Fuel utilization in subjects with carnitine palmitoyltransferase 2
RT   gene mutations.";
RL   Ann. Neurol. 57:60-66(2005).
RN   [25]
RP   ASSOCIATION OF VARIANTS CYS-352 AND ILE-368 WITH SUSCEPTIBILITY TO
RP   IIAE4.
RX   PubMed=15811315; DOI=10.1016/j.febslet.2005.02.050;
RA   Chen Y., Mizuguchi H., Yao D., Ide M., Kuroda Y., Shigematsu Y.,
RA   Yamaguchi S., Yamaguchi M., Kinoshita M., Kido H.;
RT   "Thermolabile phenotype of carnitine palmitoyltransferase II
RT   variations as a predisposing factor for influenza-associated
RT   encephalopathy.";
RL   FEBS Lett. 579:2040-2044(2005).
RN   [26]
RP   VARIANT VAL-647, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17488105; DOI=10.1021/pr0700908;
RA   Bunger M.K., Cargile B.J., Sevinsky J.R., Deyanova E., Yates N.A.,
RA   Hendrickson R.C., Stephenson J.L. Jr.;
RT   "Detection and validation of non-synonymous coding SNPs from
RT   orthogonal analysis of shotgun proteomics data.";
RL   J. Proteome Res. 6:2331-2340(2007).
RN   [27]
RP   VARIANTS CYS-352; ILE-368; LEU-504; LEU-605 AND VAL-647, AND
RP   CHARACTERIZATION OF VARIANTS CYS-352 AND ILE-368.
RX   PubMed=18306170; DOI=10.1002/humu.20717;
RA   Yao D., Mizuguchi H., Yamaguchi M., Yamada H., Chida J., Shikata K.,
RA   Kido H.;
RT   "Thermal instability of compound variants of carnitine
RT   palmitoyltransferase II and impaired mitochondrial fuel utilization in
RT   influenza-associated encephalopathy.";
RL   Hum. Mutat. 29:718-727(2008).
RN   [28]
RP   ASSOCIATION OF VARIANTS CYS-352 AND ILE-368 WITH SUSCEPTIBILITY TO
RP   IIAE4.
RX   PubMed=21697855; DOI=10.1038/jhg.2011.63;
RA   Mak C.M., Lam C.W., Fong N.C., Siu W.K., Lee H.C., Siu T.S., Lai C.K.,
RA   Law C.Y., Tong S.F., Poon W.T., Lam D.S., Ng H.L., Yuen Y.P., Tam S.,
RA   Que T.L., Kwong N.S., Chan A.Y.;
RT   "Fatal viral infection-associated encephalopathy in two Chinese boys:
RT   a genetically determined risk factor of thermolabile carnitine
RT   palmitoyltransferase II variants.";
RL   J. Hum. Genet. 56:617-621(2011).
CC   -!- CATALYTIC ACTIVITY: Palmitoyl-CoA + L-carnitine = CoA + L-
CC       palmitoylcarnitine.
CC   -!- PATHWAY: Lipid metabolism; fatty acid beta-oxidation.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Peripheral
CC       membrane protein; Matrix side.
CC   -!- DISEASE: Carnitine palmitoyltransferase 2 deficiency, myopathic,
CC       stress-induced (CPT2D) [MIM:255110]: An autosomal recessive
CC       disorder of mitochondrial long-chain fatty acid oxidation,
CC       characterized by recurrent myoglobinuria, episodes of muscle pain,
CC       stiffness, and rhabdomyolysis. These symptoms are exacerbated by
CC       prolonged exercise, fasting, cold, or viral infection. CPT2DM
CC       affects most frequently children or young adults, and severity of
CC       attacks is highly variable. Myoglobinuria can cause kidney failure
CC       and death. {ECO:0000269|PubMed:10090476,
CC       ECO:0000269|PubMed:11477613, ECO:0000269|PubMed:14605500,
CC       ECO:0000269|PubMed:14615409, ECO:0000269|PubMed:1528846,
CC       ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15622536,
CC       ECO:0000269|PubMed:7711730, ECO:0000269|PubMed:8358442,
CC       ECO:0000269|PubMed:8651281, ECO:0000269|PubMed:9600456,
CC       ECO:0000269|PubMed:9758712, ECO:0000269|Ref.13,
CC       ECO:0000269|Ref.17}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Carnitine palmitoyltransferase 2 deficiency, infantile
CC       (CPT2DI) [MIM:600649]: An autosomal recessive disorder of
CC       mitochondrial long-chain fatty acid oxidation, characterized by
CC       hepatic or hepato-cardio-muscular manifestations with onset in
CC       infancy. Clinical features include hypoketotic hypoglycemia,
CC       lethargy, seizures, hepatomegaly, liver dysfunction, cardiomegaly
CC       and dilated cardiomyopathy. {ECO:0000269|PubMed:1528846,
CC       ECO:0000269|PubMed:8651281}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Carnitine palmitoyltransferase 2 deficiency, lethal
CC       neonatal (CPT2DLN) [MIM:608836]: An autosomal recessive disorder
CC       of mitochondrial long-chain fatty acid oxidation with fatal
CC       outcome, presenting shortly after birth. It is characterized by
CC       respiratory distress, seizures, altered mental status,
CC       hepatomegaly, cardiomegaly, cardiac arrhythmia, and, in many
CC       cases, dysmorphic features, renal dysgenesis, and migration
CC       defects. recessive. {ECO:0000269|PubMed:11477613}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Encephalopathy, acute, infection-induced, 4 (IIAE4)
CC       [MIM:614212]: A severe neurologic complication of an infection. It
CC       manifests within days in otherwise healthy children after common
CC       viral infections, without evidence of viral infection of the brain
CC       or inflammatory cell infiltration. In affected children, high-
CC       grade fever is accompanied within 12 to 48 hours by febrile
CC       convulsions, often leading to coma, multiple-organ failure, brain
CC       edema, and high morbidity and mortality. The infections are
CC       usually viral, particularly influenza, although other viruses and
CC       even mycoplasma have been found to cause the disorder.
CC       {ECO:0000269|PubMed:15811315, ECO:0000269|PubMed:21697855}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry. CPT2 polymorphic
CC       variants do not cause classical carnitine palmitoyltransferase 2
CC       deficiency, and patients harboring any of them are asymptomatic
CC       most of the time. However, they are prone to viral infection (high
CC       fever)-related encephalopathy (PubMed:21697855).
CC       {ECO:0000269|PubMed:21697855}.
CC   -!- SIMILARITY: Belongs to the carnitine/choline acetyltransferase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U09648; AAB60383.1; -; mRNA.
DR   EMBL; M58581; AAB59462.1; -; mRNA.
DR   EMBL; U09646; AAB60382.1; -; Genomic_DNA.
DR   EMBL; U09642; AAB60382.1; JOINED; Genomic_DNA.
DR   EMBL; U09643; AAB60382.1; JOINED; Genomic_DNA.
DR   EMBL; U09644; AAB60382.1; JOINED; Genomic_DNA.
DR   EMBL; U09645; AAB60382.1; JOINED; Genomic_DNA.
DR   EMBL; AK312687; BAG35567.1; -; mRNA.
DR   EMBL; AL606760; CAI18907.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06753.1; -; Genomic_DNA.
DR   EMBL; BC002445; AAH02445.1; -; mRNA.
DR   EMBL; BC005172; AAH05172.1; -; mRNA.
DR   CCDS; CCDS575.1; -.
DR   PIR; A39018; A39018.
DR   RefSeq; NP_000089.1; NM_000098.2.
DR   UniGene; Hs.713535; -.
DR   ProteinModelPortal; P23786; -.
DR   SMR; P23786; -.
DR   BioGrid; 107767; 34.
DR   IntAct; P23786; 2.
DR   MINT; MINT-3010089; -.
DR   STRING; 9606.ENSP00000360541; -.
DR   BindingDB; P23786; -.
DR   ChEMBL; CHEMBL3238; -.
DR   DrugBank; DB00583; L-Carnitine.
DR   DrugBank; DB01074; Perhexiline.
DR   SwissLipids; SLP:000001044; -.
DR   iPTMnet; P23786; -.
DR   PhosphoSitePlus; P23786; -.
DR   SwissPalm; P23786; -.
DR   BioMuta; CPT2; -.
DR   DMDM; 416836; -.
DR   REPRODUCTION-2DPAGE; IPI00012912; -.
DR   EPD; P23786; -.
DR   MaxQB; P23786; -.
DR   PaxDb; P23786; -.
DR   PeptideAtlas; P23786; -.
DR   PRIDE; P23786; -.
DR   Ensembl; ENST00000371486; ENSP00000360541; ENSG00000157184.
DR   GeneID; 1376; -.
DR   KEGG; hsa:1376; -.
DR   UCSC; uc001cvb.4; human.
DR   CTD; 1376; -.
DR   DisGeNET; 1376; -.
DR   GeneCards; CPT2; -.
DR   GeneReviews; CPT2; -.
DR   HGNC; HGNC:2330; CPT2.
DR   HPA; HPA028201; -.
DR   HPA; HPA028202; -.
DR   HPA; HPA028214; -.
DR   MalaCards; CPT2; -.
DR   MIM; 255110; phenotype.
DR   MIM; 600649; phenotype.
DR   MIM; 600650; gene.
DR   MIM; 608836; phenotype.
DR   MIM; 614212; phenotype.
DR   neXtProt; NX_P23786; -.
DR   OpenTargets; ENSG00000157184; -.
DR   Orphanet; 263524; Acute necrotizing encephalopathy of childhood.
DR   Orphanet; 228302; Carnitine palmitoyl transferase II deficiency, myopathic form.
DR   Orphanet; 228308; Carnitine palmitoyl transferase II deficiency, neonatal form.
DR   Orphanet; 228305; Carnitine palmitoyl transferase II deficiency, severe infantile form.
DR   PharmGKB; PA26849; -.
DR   eggNOG; KOG3719; Eukaryota.
DR   eggNOG; ENOG410XNZ9; LUCA.
DR   GeneTree; ENSGT00550000074786; -.
DR   HOGENOM; HOG000007446; -.
DR   HOVERGEN; HBG098001; -.
DR   InParanoid; P23786; -.
DR   KO; K08766; -.
DR   OMA; FNPFMAF; -.
DR   OrthoDB; EOG091G0697; -.
DR   PhylomeDB; P23786; -.
DR   TreeFam; TF315202; -.
DR   BioCyc; MetaCyc:HS08187-MONOMER; -.
DR   BRENDA; 2.3.1.21; 2681.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-200425; Import of palmitoyl-CoA into the mitochondrial matrix.
DR   UniPathway; UPA00659; -.
DR   ChiTaRS; CPT2; human.
DR   GeneWiki; Carnitine_palmitoyltransferase_II; -.
DR   GenomeRNAi; 1376; -.
DR   PRO; PR:P23786; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000157184; -.
DR   CleanEx; HS_CPT2; -.
DR   ExpressionAtlas; P23786; baseline and differential.
DR   Genevisible; P23786; HS.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0004095; F:carnitine O-palmitoyltransferase activity; EXP:Reactome.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IEA:UniProtKB-UniPathway.
DR   InterPro; IPR000542; Carn_acyl_trans.
DR   PANTHER; PTHR22589; PTHR22589; 1.
DR   Pfam; PF00755; Carn_acyltransf; 1.
DR   PROSITE; PS00439; ACYLTRANSF_C_1; 1.
DR   PROSITE; PS00440; ACYLTRANSF_C_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Acyltransferase; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Fatty acid metabolism;
KW   Lipid metabolism; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Polymorphism; Reference proteome;
KW   Transferase; Transit peptide; Transport.
FT   TRANSIT       1     25       Mitochondrion.
FT   CHAIN        26    658       Carnitine O-palmitoyltransferase 2,
FT                                mitochondrial.
FT                                /FTId=PRO_0000004424.
FT   TOPO_DOM     26    178       Mitochondrial matrix. {ECO:0000250}.
FT   INTRAMEM    179    208       Note=Mitochondrial inner membrane.
FT                                {ECO:0000250}.
FT   TOPO_DOM    209    658       Mitochondrial matrix. {ECO:0000250}.
FT   REGION      452    464       Coenzyme A binding. {ECO:0000250}.
FT   ACT_SITE    372    372       Proton acceptor. {ECO:0000250}.
FT   BINDING     486    486       Carnitine. {ECO:0000250}.
FT   BINDING     488    488       Carnitine. {ECO:0000250}.
FT   BINDING     499    499       Carnitine. {ECO:0000250}.
FT   MOD_RES      69     69       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES      79     79       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES      85     85       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     239    239       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     239    239       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     424    424       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     439    439       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     510    510       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     510    510       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     544    544       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   MOD_RES     544    544       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52825}.
FT   VARIANT      50     50       P -> H (in CPT2D; muscular type;
FT                                dbSNP:rs28936674).
FT                                {ECO:0000269|PubMed:15622536,
FT                                ECO:0000269|PubMed:7711730}.
FT                                /FTId=VAR_001391.
FT   VARIANT     113    113       S -> L (in CPT2D; muscular form; frequent
FT                                mutation; dbSNP:rs74315294).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15622536,
FT                                ECO:0000269|PubMed:8358442,
FT                                ECO:0000269|PubMed:9758712}.
FT                                /FTId=VAR_001392.
FT   VARIANT     151    151       R -> Q (in CPT2D; dbSNP:rs515726177).
FT                                {ECO:0000269|PubMed:14605500,
FT                                ECO:0000269|PubMed:9758712}.
FT                                /FTId=VAR_020540.
FT   VARIANT     174    174       E -> K (in CPT2D; muscular type;
FT                                dbSNP:rs28936674).
FT                                {ECO:0000269|PubMed:9600456}.
FT                                /FTId=VAR_001393.
FT   VARIANT     210    210       Y -> D (in CPT2D).
FT                                {ECO:0000269|PubMed:14605500}.
FT                                /FTId=VAR_020541.
FT   VARIANT     213    213       D -> G (in CPT2D; dbSNP:rs74315300).
FT                                {ECO:0000269|PubMed:15622536}.
FT                                /FTId=VAR_037976.
FT   VARIANT     214    214       M -> T (in CPT2D; dbSNP:rs515726174).
FT                                {ECO:0000269|Ref.17}.
FT                                /FTId=VAR_007966.
FT   VARIANT     227    227       P -> L (in CPT2D; dbSNP:rs74315298).
FT                                {ECO:0000269|PubMed:9758712,
FT                                ECO:0000269|Ref.13}.
FT                                /FTId=VAR_007967.
FT   VARIANT     296    296       R -> Q (in CPT2D; dbSNP:rs764849762).
FT                                {ECO:0000269|PubMed:14605500,
FT                                ECO:0000269|PubMed:14615409}.
FT                                /FTId=VAR_020542.
FT   VARIANT     352    352       F -> C (polymorphism associated with
FT                                susceptibility to IIAE4; 3-fold decrease
FT                                of affinity for L-carnitine; lower
FT                                thermal stability compared to wild-type;
FT                                dbSNP:rs2229291).
FT                                {ECO:0000269|PubMed:15811315,
FT                                ECO:0000269|PubMed:18306170,
FT                                ECO:0000269|PubMed:21697855,
FT                                ECO:0000269|PubMed:9600456}.
FT                                /FTId=VAR_001394.
FT   VARIANT     368    368       V -> I (common polymorphism associated
FT                                with susceptibility to IIAE4; no effect
FT                                on activity; does not affect affinity for
FT                                L-carnitine; lower thermal stability
FT                                compared to wild-type; dbSNP:rs1799821).
FT                                {ECO:0000269|PubMed:14605500,
FT                                ECO:0000269|PubMed:1528846,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18306170,
FT                                ECO:0000269|PubMed:9600456,
FT                                ECO:0000269|PubMed:9758712}.
FT                                /FTId=VAR_001395.
FT   VARIANT     383    383       F -> Y (in CPT2D; hepatocardiomuscular
FT                                form; dbSNP:rs28936673).
FT                                {ECO:0000269|PubMed:9600456}.
FT                                /FTId=VAR_001396.
FT   VARIANT     448    448       F -> L (in CPT2D; dbSNP:rs74315297).
FT                                {ECO:0000269|Ref.17}.
FT                                /FTId=VAR_007968.
FT   VARIANT     479    479       Y -> F (in CPT2D; dbSNP:rs749895856).
FT                                {ECO:0000269|Ref.17}.
FT                                /FTId=VAR_007969.
FT   VARIANT     503    503       R -> C (in CPT2D; dbSNP:rs74315296).
FT                                {ECO:0000269|PubMed:10090476}.
FT                                /FTId=VAR_007970.
FT   VARIANT     504    504       P -> L (in a patient with IIAE4;
FT                                dbSNP:rs368311455).
FT                                {ECO:0000269|PubMed:18306170}.
FT                                /FTId=VAR_066567.
FT   VARIANT     549    549       G -> D (in CPT2D; dbSNP:rs186044004).
FT                                {ECO:0000269|PubMed:10090476}.
FT                                /FTId=VAR_007971.
FT   VARIANT     550    550       Q -> R (in CPT2D).
FT                                {ECO:0000269|PubMed:9758712}.
FT                                /FTId=VAR_020543.
FT   VARIANT     553    553       D -> N (in CPT2D; dbSNP:rs28936376).
FT                                {ECO:0000269|PubMed:7711730}.
FT                                /FTId=VAR_001397.
FT   VARIANT     588    588       S -> C (in dbSNP:rs1871748).
FT                                /FTId=VAR_011741.
FT   VARIANT     600    600       G -> R (in CPT2D).
FT                                {ECO:0000269|PubMed:14605500}.
FT                                /FTId=VAR_020544.
FT   VARIANT     604    604       P -> S (in CPT2D).
FT                                {ECO:0000269|PubMed:9758712}.
FT                                /FTId=VAR_020545.
FT   VARIANT     605    605       V -> L (in a patient with IIAE4;
FT                                dbSNP:rs751557097).
FT                                {ECO:0000269|PubMed:18306170}.
FT                                /FTId=VAR_066568.
FT   VARIANT     628    628       Y -> S (in CPT2DI; hepatocardiomuscular
FT                                form; dbSNP:rs28936673).
FT                                {ECO:0000269|PubMed:8651281}.
FT                                /FTId=VAR_001398.
FT   VARIANT     631    631       R -> C (in CPT2DI; early-onset
FT                                hepatocardiomuscular form;
FT                                dbSNP:rs74315293).
FT                                {ECO:0000269|PubMed:1528846}.
FT                                /FTId=VAR_001399.
FT   VARIANT     647    647       M -> V (common polymorphism; confirmed at
FT                                protein level; dbSNP:rs1799822).
FT                                {ECO:0000269|PubMed:14605500,
FT                                ECO:0000269|PubMed:1528846,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17488105,
FT                                ECO:0000269|PubMed:18306170,
FT                                ECO:0000269|PubMed:9600456,
FT                                ECO:0000269|PubMed:9758712}.
FT                                /FTId=VAR_001400.
SQ   SEQUENCE   658 AA;  73777 MW;  6444B75ACD57140F CRC64;
     MVPRLLLRAW PRGPAVGPGA PSRPLSAGSG PGQYLQRSIV PTMHYQDSLP RLPIPKLEDT
     IRRYLSAQKP LLNDGQFRKT EQFCKSFENG IGKELHEQLV ALDKQNKHTS YISGPWFDMY
     LSARDSVVLN FNPFMAFNPD PKSEYNDQLT RATNMTVSAI RFLKTLRAGL LEPEVFHLNP
     AKSDTITFKR LIRFVPSSLS WYGAYLVNAY PLDMSQYFRL FNSTRLPKPS RDELFTDDKA
     RHLLVLRKGN FYIFDVLDQD GNIVSPSEIQ AHLKYILSDS SPAPEFPLAY LTSENRDIWA
     ELRQKLMSSG NEESLRKVDS AVFCLCLDDF PIKDLVHLSH NMLHGDGTNR WFDKSFNLII
     AKDGSTAVHF EHSWGDGVAV LRFFNEVFKD STQTPAVTPQ SQPATTDSTV TVQKLNFELT
     DALKTGITAA KEKFDATMKT LTIDCVQFQR GGKEFLKKQK LSPDAVAQLA FQMAFLRQYG
     QTVATYESCS TAAFKHGRTE TIRPASVYTK RCSEAFVREP SRHSAGELQQ MMVECSKYHG
     QLTKEAAMGQ GFDRHLFALR HLAAAKGIIL PELYLDPAYG QINHNVLSTS TLSSPAVNLG
     GFAPVVSDGF GVGYAVHDNW IGCNVSSYPG RNAREFLQCV EKALEDMFDA LEGKSIKS
//
